NANBOLIC-PH - Nandrolone Phenylpropionate 100mg/200mg/275mg

Category:- Hormones | Type:- Injection

Each ml contains: Nandrolone Phenylpropionate BP 100 mg

PHARMACOLOGICAL ACTION:
Nanbolic-PH is an injectable anabolic preparation. After injection, nandrolone phenylpropionate is gradually released from the intramuscular depot and subsequently hydrolysed into nandrolone.

INDICATIONS:
Certain cases of disseminated breast cancer in women. Osteoporosis due to androgen deficiency in hypogonadal males.

CONTRA-INDICATIONS: Not intended for use in children.

Known or suspected prostatic carcinoma and mammary carcinoma in the male.

Not intended for use in female patients other than those with disseminated breast cancer.

Contraindicated in nephrosis or the nephrotic phase of nephritis, cardiac and renal failure, hypercalcaemia, oedema, jaundice, liver disease with impaired bilirubin excretion, testicular and hepatic carcinoma.

DOSAGE AND DIRECTIONS FOR USE:
Nanbolic-PH should be administered by deep intramuscular injection.

Adult dose: 50-100 mg every 3 weeks.

SIDE-EFFECTS AND SPECIAL PRECAUTIONS:
Virilisation which appears in sensitive women as hoarseness, acne, hirsutism, and increased libido; in prepubertal boys as an increased frequency of erections and phallic enlargement, and in girls as an increase of pubic hair and clitoral hypertrophy. Hoarseness may be the first symptom of vocal change which may end in a long-lasting, sometimes irreversible deepening of the voice.

OTHER ADVERSE REACTIONS MAY INCLUDE:
Oligospermia and decreased ejaculatory volume; Suppression of ovarian activity, atrophy of the breasts and endometrial tissue. Amenorrhoea and inhibition of  spermatogenesis. Water and salt retention. Premature epiphyseal closure. If signs of virilisation develop, treatment should be discontinued. Increase in nitrogen retention and skeletal weight; Oedema; Increased vascularity of the skin; Increased growth of the bone; Elderly males may become over-stimulated.

PATIENTS WITH THE FOLLOWING CONDITIONS SHOULD BE MONITORED:
Latent or overt cardiac failure, renal dysfunction, hypertension, epilepsy or migraine (or a history of these conditions), since anabolic steroids may induce salt and fluid retention; diabetes, since anabolic steroids may improve the glucose tolerance and decrease the need for insulin or other antidiabetic drugs; incomplete statural growth, since anabolic steroids in high dosages may accelerate epiphyseal closure; skeletal metastases, since anabolic steroids may induce hypercalcaemia and hypercalciuria in
these patients.

INTERACTIONS:
Liver-enzyme-inducing agents may reduce the effects of Nanbolic-PH by enhancing its metabolism in the liver.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT: See "Side-effects and special precautions". Treatment is symptomatic and supportive.

PRESENTATION:
Nanbolic-PH 100 mg/mL:
10 x 1 ml clear glass ampoules

STORAGE INSTRUCTIONS:
Nanbolic-PH should be stored at controlled room temperatures below 30°C and protected from light. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. If it has expired or is damaged, return it to your pharmacist for disposal.

Keep out of reach of children.

Manufactured by :
COOPER PHARMA LIMITED